| USA TODAY
President Donald Trump previously reported that he won capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the makers of two of the drugs he took as part of his COVID-19 treatment plan.
According to a 2017 financial disclosure form filed with the US Bureau of Government Ethics in June 2017, Trump realized a capital gain of $ 50,001 to $ 100,000 for Regeneron Pharmaceuticals and of $ 100,001 to $ 1 million for Gilead Sciences Inc. The form indicates the information was as of April 15. , 2017.
Trump’s subsequent disclosure forms, including his 2020 form signed on July 31, did not mention Regeneron or Gilead.
Trump was given a single 8-gram dose of Regeneron’s polyclonal antibody cocktail as a precaution, according to his doctor Sean Conley. The antibody cocktail is in four advanced clinical trials, and its safety and efficacy have not been fully evaluated by any regulator, the company said on its webpage.
Save better, spend better: Money tips and tricks delivered straight to your inbox. register here
As part of Operation Warp Speed, New York-based Regeneron won a $ 450 million federal contract in July to manufacture and supply the company’s REGN-COV2 antibody cocktail.
The New York Times reported on Friday that Regeneron Chief Executive Officer Dr. Leonard S. The Drug Administration cleared it.
Mask compliance: Now that Trump has tested positive for COVID-19, will shoppers be more compliant with mask warrants in stores?
Trump COVID-19: President’s diagnosis raises questions about what to do if your boss isn’t wearing a mask
“All we can say is that they asked to be able to use it, and we were happy to do so,” Schleifer told The Times, calling it a “compassionate use.” Trump is not the first patient to try the investigational treatment outside of the clinical trial through compassionate use.
“When it’s the President of the United States, of course, that gets – obviously – our attention,” Schleifer told The Times. Regeneron stock rose $ 19.20 per share after hours.
Trump is also taking Gilead’s remdesivir, which has been cleared for COVID-19 patients by the FDA under an emergency use statement. The trials have shown efficacy in certain circumstances.
Remdesivir received cautious approval in April from Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, when it was announced as a new tool to fight the virus during of a new presidential conference.
What you need to know about remdesivir: Trump gave remdesivir to fight his COVID-19 infection
Anti-mask movement: Trump’s COVID-19 diagnosis doesn’t slow virulent Facebook anti-mask movement
It was not clear on Saturday whether the president currently has direct stakes in Regeneron and Gilead, but it appears he still has an interest in hydroxychloroquine, a drug he has repeatedly touted as a treatment for COVID -19 despite warnings about its effectiveness.
Trump’s latest financial disclosure form reports his family trusts’ investments in a Dodge & Cox mutual fund. A New York Times article published in April said the fund’s largest stake would be in Sanofi, the pharmaceutical company that is a major producer of hydroxychloroquine.
Hydroxychloroquine is an arthritis medication that can also be used as a preventative or in the treatment of malaria, an infection of red blood cells transmitted by a mosquito bite, according to the Mayo Clinic.
Contribution: Michael Collins, Grace Hauck, Chris Woodyard, Nicholas Wu, Sean Rossman, John Fritze, Adrianna Rodriguez, Elizabeth Weise et Karen Weintraub, USA TODAY
Follow USA TODAY reporter Kelly Tyko on Twitter: @KellyTyko